Insmed, Inc. $INSM Holdings Raised by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 26.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,581 shares of the biopharmaceutical company’s stock after purchasing an additional 13,400 shares during the quarter. Handelsbanken Fonder AB’s holdings in Insmed were worth $11,066,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of INSM. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. CoreCap Advisors LLC bought a new stake in shares of Insmed during the fourth quarter valued at about $27,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares in the last quarter. GraniteShares Advisors LLC bought a new stake in shares of Insmed during the fourth quarter valued at about $30,000. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 151 shares in the last quarter.

Insmed Price Performance

Shares of Insmed stock opened at $109.53 on Friday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The company’s 50-day moving average price is $138.55 and its two-hundred day moving average price is $161.25. Insmed, Inc. has a 52 week low of $64.85 and a 52 week high of $212.75. The stock has a market cap of $23.74 billion, a PE ratio of -19.05 and a beta of 0.89.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.42) earnings per share. As a group, sell-side analysts anticipate that Insmed, Inc. will post -2.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This represents a 45.19% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 150,494 shares of company stock valued at $23,846,784. 2.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Friday, May 8th. Roth Mkm restated a “buy” rating and set a $212.00 price objective on shares of Insmed in a research note on Friday, April 17th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $166.00 to $212.00 in a research note on Monday, March 30th. Stifel Nicolaus boosted their price target on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Wells Fargo & Company dropped their price target on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus target price of $210.95.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.